{"id":8124,"date":"2026-04-16T11:01:13","date_gmt":"2026-04-16T11:01:13","guid":{"rendered":"https:\/\/intnews.it\/?p=8124"},"modified":"2026-04-16T11:01:16","modified_gmt":"2026-04-16T11:01:16","slug":"the-fda-approval-enigma-travere-therapeutics-filspari-case","status":"publish","type":"post","link":"https:\/\/intnews.it\/en\/the-fda-approval-enigma-travere-therapeutics-filspari-case\/","title":{"rendered":"The FDA Approval Enigma: Travere Therapeutics\u2019 Filspari Case"},"content":{"rendered":"\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong>Key Takeaways<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Scenario:<\/strong> The FDA granted full approval to Filspari (sparsentan) for IgA nephropathy despite the drug&#8217;s failure to demonstrate statistically significant superiority in long-term kidney function preservation.<\/li>\n\n\n\n<li><strong>Business Impact:<\/strong> This decision establishes a pivotal precedent, suggesting that biomarker reduction (proteinuria) can override functional clinical endpoints in regulatory pathways.<\/li>\n\n\n\n<li><strong>Data Point:<\/strong> The Phase 3 PROTECT study yielded a 40% reduction in proteinuria but missed the primary endpoint of slowing the eGFR decline compared to irbesartan.<\/li>\n<\/ul>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\">PROTECT Study Analysis: Why eGFR Data Underperformed<\/h2>\n\n\n\n<p>The clinical trial conducted by Travere Therapeutics revealed a distinct gap between biochemical response and functional outcomes. Although Filspari achieved a robust reduction in urinary protein levels, the rate of kidney function decline (eGFR slope) did not diverge significantly from the control group over a two-year period. Consequently, clinical experts remain divided on whether the drug truly delays the progression toward end-stage renal disease. [LINK INTERNO: Clinical Pharmacology]\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\">Regulatory Flexibility vs. Scientific Rigor: The FDA\u2019s New Stance<\/h2>\n\n\n\n<p>The U.S. regulatory agency exercised maximum flexibility by prioritizing patient access to treatments for rare, debilitating diseases over rigid functional data requirements. This shift reflects an <a href=\"https:\/\/www.fda.gov\/\">FDA Regulationstrategy<\/a> designed to catalyze innovation in orphan drug development. Nevertheless, critics argue that such flexibility might inadvertently lower the efficacy threshold required for drug commercialization.<\/p>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\">Implications for Biotech and Pharma C-Level Executives<\/h3>\n\n\n\n<p>For industry leaders, the <a href=\"https:\/\/travere.com\/\">Travere<\/a> case demonstrates that regulatory risk can be mitigated through strategic surrogate endpoint management. Furthermore, executives must monitor the potential impact on payer negotiations. Insurance providers may demand additional real-world evidence of functional benefit before committing to high-cost coverage in the absence of definitive outcome data.<\/p>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\">Financial Projections and Pricing Sustainability<\/h2>\n\n\n\n<p>Filspari\u2019s commercial success now hinges on market penetration and Travere\u2019s ability to establish the drug as a standard of care despite emerging clinical limitations. Maintaining a premium price point requires convincing nephrologists that proteinuria reduction is a sufficient surrogate for long-term health. Revenue trajectories for 2026 will serve as a bellwether for market acceptance of biomarker-based therapeutic approvals. <a href=\"https:\/\/intnews.it\/en\/predictive-cardiology-2026-lai-che-vede-linfarto-mesi-prima-dei-sintomi\/\">Leggi un articolo simile a questo.<\/a> <\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Technical analysis of the FDA approval of Filspari (sparsentan) and its implications for the biotech industry and IgA nephropathy treatment.<\/p>\n","protected":false},"author":9,"featured_media":8122,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[83,84],"tags":[],"class_list":{"0":"post-8124","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sustainability","8":"category-technologies"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The FDA Approval Enigma: Travere Therapeutics\u2019 Filspari Case - INT News<\/title>\n<meta name=\"description\" content=\"Technical analysis of the FDA approval of Filspari (sparsentan) and its implications for the biotech industry and IgA nephropathy treatment. Travere Therapeutics\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/intnews.it\/en\/the-fda-approval-enigma-travere-therapeutics-filspari-case\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The FDA Approval Enigma: Travere Therapeutics\u2019 Filspari Case - INT News\" \/>\n<meta property=\"og:description\" content=\"Technical analysis of the FDA approval of Filspari (sparsentan) and its implications for the biotech industry and IgA nephropathy treatment. Travere Therapeutics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/intnews.it\/en\/the-fda-approval-enigma-travere-therapeutics-filspari-case\/\" \/>\n<meta property=\"og:site_name\" content=\"INT News\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-16T11:01:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-16T11:01:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/intnews.it\/wp-content\/uploads\/2026\/04\/Travere-Therapeutics.png\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"480\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Amministrazione\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Amministrazione\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/intnews.it\\\/en\\\/the-fda-approval-enigma-travere-therapeutics-filspari-case\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/intnews.it\\\/en\\\/the-fda-approval-enigma-travere-therapeutics-filspari-case\\\/\"},\"author\":{\"name\":\"Amministrazione\",\"@id\":\"https:\\\/\\\/intnews.it\\\/en\\\/#\\\/schema\\\/person\\\/16e764f65f0f425b8f18a84d24a9840b\"},\"headline\":\"The FDA Approval Enigma: Travere Therapeutics\u2019 Filspari Case\",\"datePublished\":\"2026-04-16T11:01:13+00:00\",\"dateModified\":\"2026-04-16T11:01:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/intnews.it\\\/en\\\/the-fda-approval-enigma-travere-therapeutics-filspari-case\\\/\"},\"wordCount\":347,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/intnews.it\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/intnews.it\\\/en\\\/the-fda-approval-enigma-travere-therapeutics-filspari-case\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/intnews.it\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Travere-Therapeutics.png\",\"articleSection\":[\"Sustainability\",\"Technologies\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/intnews.it\\\/en\\\/the-fda-approval-enigma-travere-therapeutics-filspari-case\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/intnews.it\\\/en\\\/the-fda-approval-enigma-travere-therapeutics-filspari-case\\\/\",\"url\":\"https:\\\/\\\/intnews.it\\\/en\\\/the-fda-approval-enigma-travere-therapeutics-filspari-case\\\/\",\"name\":\"The FDA Approval Enigma: Travere Therapeutics\u2019 Filspari Case - INT News\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/intnews.it\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/intnews.it\\\/en\\\/the-fda-approval-enigma-travere-therapeutics-filspari-case\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/intnews.it\\\/en\\\/the-fda-approval-enigma-travere-therapeutics-filspari-case\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/intnews.it\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Travere-Therapeutics.png\",\"datePublished\":\"2026-04-16T11:01:13+00:00\",\"dateModified\":\"2026-04-16T11:01:16+00:00\",\"description\":\"Technical analysis of the FDA approval of Filspari (sparsentan) and its implications for the biotech industry and IgA nephropathy treatment. Travere Therapeutics\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/intnews.it\\\/en\\\/the-fda-approval-enigma-travere-therapeutics-filspari-case\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/intnews.it\\\/en\\\/the-fda-approval-enigma-travere-therapeutics-filspari-case\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/intnews.it\\\/en\\\/the-fda-approval-enigma-travere-therapeutics-filspari-case\\\/#primaryimage\",\"url\":\"https:\\\/\\\/intnews.it\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Travere-Therapeutics.png\",\"contentUrl\":\"https:\\\/\\\/intnews.it\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Travere-Therapeutics.png\",\"width\":960,\"height\":480},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/intnews.it\\\/en\\\/the-fda-approval-enigma-travere-therapeutics-filspari-case\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/intnews.it\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The FDA Approval Enigma: Travere Therapeutics\u2019 Filspari Case\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/intnews.it\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/intnews.it\\\/en\\\/\",\"name\":\"INT News\",\"description\":\"innovation tomorrow\",\"publisher\":{\"@id\":\"https:\\\/\\\/intnews.it\\\/en\\\/#organization\"},\"alternateName\":\"Innovation Tomorrow\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/intnews.it\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/intnews.it\\\/en\\\/#organization\",\"name\":\"INT News\",\"alternateName\":\"Innovation Tomorrow\",\"url\":\"https:\\\/\\\/intnews.it\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/intnews.it\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/intnews.it\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/int-logo2.webp\",\"contentUrl\":\"https:\\\/\\\/intnews.it\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/int-logo2.webp\",\"width\":538,\"height\":232,\"caption\":\"INT News\"},\"image\":{\"@id\":\"https:\\\/\\\/intnews.it\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/intnews.it\\\/en\\\/#\\\/schema\\\/person\\\/16e764f65f0f425b8f18a84d24a9840b\",\"name\":\"Amministrazione\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cadff1b6f5182664030faecf14b842539255149e35ed6691b8b4fb917c59b7b8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cadff1b6f5182664030faecf14b842539255149e35ed6691b8b4fb917c59b7b8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cadff1b6f5182664030faecf14b842539255149e35ed6691b8b4fb917c59b7b8?s=96&d=mm&r=g\",\"caption\":\"Amministrazione\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The FDA Approval Enigma: Travere Therapeutics\u2019 Filspari Case - INT News","description":"Technical analysis of the FDA approval of Filspari (sparsentan) and its implications for the biotech industry and IgA nephropathy treatment. Travere Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/intnews.it\/en\/the-fda-approval-enigma-travere-therapeutics-filspari-case\/","og_locale":"en_US","og_type":"article","og_title":"The FDA Approval Enigma: Travere Therapeutics\u2019 Filspari Case - INT News","og_description":"Technical analysis of the FDA approval of Filspari (sparsentan) and its implications for the biotech industry and IgA nephropathy treatment. Travere Therapeutics","og_url":"https:\/\/intnews.it\/en\/the-fda-approval-enigma-travere-therapeutics-filspari-case\/","og_site_name":"INT News","article_published_time":"2026-04-16T11:01:13+00:00","article_modified_time":"2026-04-16T11:01:16+00:00","og_image":[{"width":960,"height":480,"url":"https:\/\/intnews.it\/wp-content\/uploads\/2026\/04\/Travere-Therapeutics.png","type":"image\/png"}],"author":"Amministrazione","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Amministrazione","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/intnews.it\/en\/the-fda-approval-enigma-travere-therapeutics-filspari-case\/#article","isPartOf":{"@id":"https:\/\/intnews.it\/en\/the-fda-approval-enigma-travere-therapeutics-filspari-case\/"},"author":{"name":"Amministrazione","@id":"https:\/\/intnews.it\/en\/#\/schema\/person\/16e764f65f0f425b8f18a84d24a9840b"},"headline":"The FDA Approval Enigma: Travere Therapeutics\u2019 Filspari Case","datePublished":"2026-04-16T11:01:13+00:00","dateModified":"2026-04-16T11:01:16+00:00","mainEntityOfPage":{"@id":"https:\/\/intnews.it\/en\/the-fda-approval-enigma-travere-therapeutics-filspari-case\/"},"wordCount":347,"commentCount":0,"publisher":{"@id":"https:\/\/intnews.it\/en\/#organization"},"image":{"@id":"https:\/\/intnews.it\/en\/the-fda-approval-enigma-travere-therapeutics-filspari-case\/#primaryimage"},"thumbnailUrl":"https:\/\/intnews.it\/wp-content\/uploads\/2026\/04\/Travere-Therapeutics.png","articleSection":["Sustainability","Technologies"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/intnews.it\/en\/the-fda-approval-enigma-travere-therapeutics-filspari-case\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/intnews.it\/en\/the-fda-approval-enigma-travere-therapeutics-filspari-case\/","url":"https:\/\/intnews.it\/en\/the-fda-approval-enigma-travere-therapeutics-filspari-case\/","name":"The FDA Approval Enigma: Travere Therapeutics\u2019 Filspari Case - INT News","isPartOf":{"@id":"https:\/\/intnews.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/intnews.it\/en\/the-fda-approval-enigma-travere-therapeutics-filspari-case\/#primaryimage"},"image":{"@id":"https:\/\/intnews.it\/en\/the-fda-approval-enigma-travere-therapeutics-filspari-case\/#primaryimage"},"thumbnailUrl":"https:\/\/intnews.it\/wp-content\/uploads\/2026\/04\/Travere-Therapeutics.png","datePublished":"2026-04-16T11:01:13+00:00","dateModified":"2026-04-16T11:01:16+00:00","description":"Technical analysis of the FDA approval of Filspari (sparsentan) and its implications for the biotech industry and IgA nephropathy treatment. Travere Therapeutics","breadcrumb":{"@id":"https:\/\/intnews.it\/en\/the-fda-approval-enigma-travere-therapeutics-filspari-case\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/intnews.it\/en\/the-fda-approval-enigma-travere-therapeutics-filspari-case\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/intnews.it\/en\/the-fda-approval-enigma-travere-therapeutics-filspari-case\/#primaryimage","url":"https:\/\/intnews.it\/wp-content\/uploads\/2026\/04\/Travere-Therapeutics.png","contentUrl":"https:\/\/intnews.it\/wp-content\/uploads\/2026\/04\/Travere-Therapeutics.png","width":960,"height":480},{"@type":"BreadcrumbList","@id":"https:\/\/intnews.it\/en\/the-fda-approval-enigma-travere-therapeutics-filspari-case\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/intnews.it\/en\/"},{"@type":"ListItem","position":2,"name":"The FDA Approval Enigma: Travere Therapeutics\u2019 Filspari Case"}]},{"@type":"WebSite","@id":"https:\/\/intnews.it\/en\/#website","url":"https:\/\/intnews.it\/en\/","name":"INT News","description":"innovation tomorrow","publisher":{"@id":"https:\/\/intnews.it\/en\/#organization"},"alternateName":"Innovation Tomorrow","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/intnews.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/intnews.it\/en\/#organization","name":"INT News","alternateName":"Innovation Tomorrow","url":"https:\/\/intnews.it\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/intnews.it\/en\/#\/schema\/logo\/image\/","url":"https:\/\/intnews.it\/wp-content\/uploads\/2023\/10\/int-logo2.webp","contentUrl":"https:\/\/intnews.it\/wp-content\/uploads\/2023\/10\/int-logo2.webp","width":538,"height":232,"caption":"INT News"},"image":{"@id":"https:\/\/intnews.it\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/intnews.it\/en\/#\/schema\/person\/16e764f65f0f425b8f18a84d24a9840b","name":"Amministrazione","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/cadff1b6f5182664030faecf14b842539255149e35ed6691b8b4fb917c59b7b8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/cadff1b6f5182664030faecf14b842539255149e35ed6691b8b4fb917c59b7b8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/cadff1b6f5182664030faecf14b842539255149e35ed6691b8b4fb917c59b7b8?s=96&d=mm&r=g","caption":"Amministrazione"}}]}},"_links":{"self":[{"href":"https:\/\/intnews.it\/en\/wp-json\/wp\/v2\/posts\/8124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/intnews.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/intnews.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/intnews.it\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/intnews.it\/en\/wp-json\/wp\/v2\/comments?post=8124"}],"version-history":[{"count":2,"href":"https:\/\/intnews.it\/en\/wp-json\/wp\/v2\/posts\/8124\/revisions"}],"predecessor-version":[{"id":8126,"href":"https:\/\/intnews.it\/en\/wp-json\/wp\/v2\/posts\/8124\/revisions\/8126"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/intnews.it\/en\/wp-json\/wp\/v2\/media\/8122"}],"wp:attachment":[{"href":"https:\/\/intnews.it\/en\/wp-json\/wp\/v2\/media?parent=8124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/intnews.it\/en\/wp-json\/wp\/v2\/categories?post=8124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/intnews.it\/en\/wp-json\/wp\/v2\/tags?post=8124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}